Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Kinin antagonists: design and activities.

J M Stewart¹, R J Vavrek

¹Department of Biochemistry, University of Colorado School of Medicine, Denver 80262.

Journal of Cardiovascular Pharmacology

|January 1, 1990

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

'Transient immediate orthostatic hypotension' is preferable to 'initial' orthostatic hypotension.

Autonomic neuroscience : basic & clinical·2025

Same author

Combination Treatment with Antigen-Specific Dual-Sized Microparticle System Plus Anti-CD3 Immunotherapy Fails to Synergize to Improve Late-Stage Type 1 Diabetes Prevention in Nonobese Diabetic Mice.

ACS biomaterials science & engineering·2020

Same author

Engineering immunomodulatory biomaterials for type 1 diabetes.

Nature reviews. Materials·2020

Same author

First Report of Colletotrichum chlorophyti Infecting Soybean Seed in Arkansas, United States.

Plant disease·2019

Same author

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Investigational new drugs·2017

Same author

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors.

Investigational new drugs·2017

Same journal

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases.

Journal of cardiovascular pharmacology·2026

Same journal

A Comprehensive Review of PCSK9 Inhibitor Therapy.

Journal of cardiovascular pharmacology·2026

Same journal

SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study.

Journal of cardiovascular pharmacology·2026

Same journal

Aspirin in primary prevention: a case for selective use.

Journal of cardiovascular pharmacology·2026

Same journal

GLP-1 Gene Therapy Trial for Obesity and Type 2 Diabetes: Towards a New Paradigm for Chronic Disease Treatment.

Journal of cardiovascular pharmacology·2026

Same journal

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis.

Journal of cardiovascular pharmacology·2026

See all related articles

Bradykinin antagonists have been developed to investigate kinin roles in health and disease. These compounds show promise for treating pain, inflammation, and asthma.

Area of Science:

Pharmacology
Biochemistry
Physiology

Background:

Bradykinins are key mediators in various physiological and pathological processes.
Understanding kinin pathways is crucial for developing targeted therapeutics.

Purpose of the Study:

To explore structural modifications of bradykinin antagonists.
To enhance antagonist potency, tissue selectivity, and enzymatic stability.

Main Methods:

Synthesis and evaluation of several hundred bradykinin analog structures.
Testing antagonist efficacy across diverse kinin-responsive tissues.

Main Results:

Identified specific structural changes conferring high potency and selectivity.
Demonstrated resistance to enzymatic degradation in optimized analogs.

Related Experiment Videos

Conclusions:

Developed potent and selective bradykinin antagonists.
These antagonists hold therapeutic potential for pain, inflammation, and asthma management.